Circadian Stage-Dependent Inhibition of Human Breast Cancer Metabolism and Growth by the Nocturnal Melatonin Signal: Consequences of Its Disruption by Light at Night in Rats and Women

The circadian production of melatonin by the pineal gland during the night provides an inhibitory signal to tissue-isolated steroid receptor SR+ and — MCF-7 human breast cancer xenografts in female nude rats. A pivotal mechanism for melatonin’s anticancer effects in vivo involves a melatonin recepto...

Full description

Saved in:
Bibliographic Details
Published inIntegrative cancer therapies Vol. 8; no. 4; pp. 347 - 353
Main Authors Blask, David E., Dauchy, Robert T., Brainard, George C., Hanifin, John P.
Format Journal Article
LanguageEnglish
Published Los Angeles, CA SAGE Publications 01.12.2009
Subjects
Online AccessGet full text
ISSN1534-7354
1552-695X
1552-695X
DOI10.1177/1534735409352320

Cover

Abstract The circadian production of melatonin by the pineal gland during the night provides an inhibitory signal to tissue-isolated steroid receptor SR+ and — MCF-7 human breast cancer xenografts in female nude rats. A pivotal mechanism for melatonin’s anticancer effects in vivo involves a melatonin receptor-mediated inhibition of linoleic acid (LA) uptake and its metabolism to mitogenically active 13-hydroxyoctadecadienoic acid (13-HODE). Exposure of (SR-) xenograft-bearing rats to increasing intensities of polychromatic white light at night suppresses melatonin while increasing tumor growth rates, DNA content, [3H]thymidine incorporation into DNA, LA uptake, 13-HODE formation, cAMP levels and ERK1/2 activation a dose-dependent manner. Similar effects occur in SR- human breast cancer xenografts perfused in situ with melatonin-depleted blood from healthy female subjects after their exposure to a single bright intensity (2800 lux) of polychromatic light at night. Additionally, SR- human breast cancer xenografts exhibit robust circadian rhythms of LA uptake, 13-HODE formation and proliferative activity. Exposure of xenograft-bearing rats to dim light at night results in the complete elimination of these rhythms which culminates in unfettered, high rates of tumor metabolism and growth. The organization of tumor metabolism and growth within circadian time structure by the oncostatic melatonin signal helps create a balance between the cancer and its host that is disrupted by host exposure to light at night. This biological mechanism may partially explain the higher risk of breast and other cancers in women working rotating night shifts and possibly others who also experience prolonged exposure to light at night.
AbstractList The circadian production of melatonin by the pineal gland during the night provides an inhibitory signal to tissue-isolated steroid receptor SR+ and — MCF-7 human breast cancer xenografts in female nude rats. A pivotal mechanism for melatonin’s anticancer effects in vivo involves a melatonin receptor-mediated inhibition of linoleic acid (LA) uptake and its metabolism to mitogenically active 13-hydroxyoctadecadienoic acid (13-HODE). Exposure of (SR-) xenograft-bearing rats to increasing intensities of polychromatic white light at night suppresses melatonin while increasing tumor growth rates, DNA content, [3H]thymidine incorporation into DNA, LA uptake, 13-HODE formation, cAMP levels and ERK1/2 activation a dose-dependent manner. Similar effects occur in SR- human breast cancer xenografts perfused in situ with melatonin-depleted blood from healthy female subjects after their exposure to a single bright intensity (2800 lux) of polychromatic light at night. Additionally, SR- human breast cancer xenografts exhibit robust circadian rhythms of LA uptake, 13-HODE formation and proliferative activity. Exposure of xenograft-bearing rats to dim light at night results in the complete elimination of these rhythms which culminates in unfettered, high rates of tumor metabolism and growth. The organization of tumor metabolism and growth within circadian time structure by the oncostatic melatonin signal helps create a balance between the cancer and its host that is disrupted by host exposure to light at night. This biological mechanism may partially explain the higher risk of breast and other cancers in women working rotating night shifts and possibly others who also experience prolonged exposure to light at night.
The circadian production of melatonin by the pineal gland during the night provides an inhibitory signal to tissue-isolated steroid receptor SR+ and - MCF-7 human breast cancer xenografts in female nude rats. A pivotal mechanism for melatonin's anticancer effects in vivo involves a melatonin receptor-mediated inhibition of linoleic acid (LA) uptake and its metabolism to mitogenically active 13-hydroxyoctadecadienoic acid (13-HODE). Exposure of (SR-) xenograft-bearing rats to increasing intensities of polychromatic white light at night suppresses melatonin while increasing tumor growth rates, DNA content, [3H]thymidine incorporation into DNA, LA uptake, 13-HODE formation, cAMP levels and ERK1/2 activation a dose-dependent manner. Similar effects occur in SR- human breast cancer xenografts perfused in situ with melatonin-depleted blood from healthy female subjects after their exposure to a single bright intensity (2800 lux) of polychromatic light at night. Additionally, SR- human breast cancer xenografts exhibit robust circadian rhythms of LA uptake, 13-HODE formation and proliferative activity. Exposure of xenograft-bearing rats to dim light at night results in the complete elimination of these rhythms which culminates in unfettered, high rates of tumor metabolism and growth. The organization of tumor metabolism and growth within circadian time structure by the oncostatic melatonin signal helps create a balance between the cancer and its host that is disrupted by host exposure to light at night. This biological mechanism may partially explain the higher risk of breast and other cancers in women working rotating night shifts and possibly others who also experience prolonged exposure to light at night.The circadian production of melatonin by the pineal gland during the night provides an inhibitory signal to tissue-isolated steroid receptor SR+ and - MCF-7 human breast cancer xenografts in female nude rats. A pivotal mechanism for melatonin's anticancer effects in vivo involves a melatonin receptor-mediated inhibition of linoleic acid (LA) uptake and its metabolism to mitogenically active 13-hydroxyoctadecadienoic acid (13-HODE). Exposure of (SR-) xenograft-bearing rats to increasing intensities of polychromatic white light at night suppresses melatonin while increasing tumor growth rates, DNA content, [3H]thymidine incorporation into DNA, LA uptake, 13-HODE formation, cAMP levels and ERK1/2 activation a dose-dependent manner. Similar effects occur in SR- human breast cancer xenografts perfused in situ with melatonin-depleted blood from healthy female subjects after their exposure to a single bright intensity (2800 lux) of polychromatic light at night. Additionally, SR- human breast cancer xenografts exhibit robust circadian rhythms of LA uptake, 13-HODE formation and proliferative activity. Exposure of xenograft-bearing rats to dim light at night results in the complete elimination of these rhythms which culminates in unfettered, high rates of tumor metabolism and growth. The organization of tumor metabolism and growth within circadian time structure by the oncostatic melatonin signal helps create a balance between the cancer and its host that is disrupted by host exposure to light at night. This biological mechanism may partially explain the higher risk of breast and other cancers in women working rotating night shifts and possibly others who also experience prolonged exposure to light at night.
Author Hanifin, John P.
Brainard, George C.
Dauchy, Robert T.
Blask, David E.
Author_xml – sequence: 1
  givenname: David E.
  surname: Blask
  fullname: Blask, David E.
  email: dblask@tulane.edu
  organization: Tulane Cancer Center and Louisiana Cancer Research Consortium, Tulane University School of Medicine, New Orleans, LA, USA
– sequence: 2
  givenname: Robert T.
  surname: Dauchy
  fullname: Dauchy, Robert T.
  organization: Tulane Cancer Center and Louisiana Cancer Research Consortium, Tulane University School of Medicine, New Orleans, LA, USA
– sequence: 3
  givenname: George C.
  surname: Brainard
  fullname: Brainard, George C.
  organization: Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA
– sequence: 4
  givenname: John P.
  surname: Hanifin
  fullname: Hanifin, John P.
  organization: Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/20042410$$D View this record in MEDLINE/PubMed
BookMark eNp9kUtv1DAUhSNURB-wZ4W8YxWwY8dO2EEK7UhDkXgIdtGNczPjKrGntiPUX9a_V2emsKgEK1_Z3znHuuc0O7LOYpa9ZPQNY0q9ZSUXipeC1rwseEGfZCesLItc1uWvo2XmIl_ej7PTEK4pLRiV5bPsuKBUFILRk-yuMV5Db8CSbxE2mJ_jDm2PNpKV3ZrOROMscQO5nKfEfPAIIZIGrEZPPmOEzo0mTARsTy68-x23pLslcYvkyuk4ewtjwkaIzpoUYTbp4h1pnA14M2NyCYv5KgZyboKfd_u45LA2m20kEMnVfkjar5CgJeanm9A-z54OMAZ88XCeZT8-ffzeXObrLxer5v0610KImDNAWsleMC0BeqqwZrISg9ScMlqjYqVkvCvKGllfVUxzqYaCqkrAoISgHT_LXh98d96lD4fYTiZoHEew6ObQKs5VVRdSJPLVAzl3E_btzpsJ_G37Z9cJoAdAexeCx-Evwmi71Nk-rjNJ5COJNhGWHUUPZvyfMD8IQ-q0vXb7IsK_-XsOm6_w
CitedBy_id crossref_primary_10_1515_med_2022_0470
crossref_primary_10_1016_j_mce_2011_07_009
crossref_primary_10_3390_en15010350
crossref_primary_10_1016_j_jphysparis_2013_03_007
crossref_primary_10_1038_srep29606
crossref_primary_10_3109_09513590_2014_978851
crossref_primary_10_1016_j_critrevonc_2017_12_018
crossref_primary_10_1038_s41416_018_0154_2
crossref_primary_10_1007_s00018_012_1161_8
crossref_primary_10_1177_1534735419889154
crossref_primary_10_1016_j_neuroscience_2011_02_003
crossref_primary_10_3109_07420528_2014_960047
crossref_primary_10_3109_07853890_2014_916990
crossref_primary_10_3928_21650799_20120529_06
crossref_primary_10_1016_j_amepre_2013_10_028
crossref_primary_10_1016_j_scitotenv_2017_07_056
crossref_primary_10_1016_j_jash_2014_08_011
crossref_primary_10_1080_10807039_2012_702608
crossref_primary_10_1097_PPO_0000000000000071
crossref_primary_10_3390_ijms222212494
crossref_primary_10_1517_14728222_2013_834890
crossref_primary_10_1158_0008_5472_CAN_10_3837
crossref_primary_10_1158_1055_9965_EPI_11_1128
crossref_primary_10_1007_s10549_013_2433_1
crossref_primary_10_1002_jez_2164
crossref_primary_10_1186_s12935_025_03649_6
crossref_primary_10_1016_j_ejca_2022_06_007
crossref_primary_10_1016_j_mce_2012_04_009
crossref_primary_10_1177_216507991206000607
crossref_primary_10_3109_07420528_2015_1027901
crossref_primary_10_1186_s13058_025_01991_1
crossref_primary_10_1016_j_mrrev_2011_12_002
crossref_primary_10_2119_molmed_2012_00077
crossref_primary_10_1111_j_1600_079X_2011_00934_x
crossref_primary_10_1080_2159256X_2015_1037416
crossref_primary_10_1093_ehjcvp_pvv037
crossref_primary_10_1158_1055_9965_EPI_12_1377
crossref_primary_10_3390_ijms21207736
crossref_primary_10_1038_s42003_019_0548_6
crossref_primary_10_1016_j_lfs_2017_02_008
crossref_primary_10_1507_endocrj_EJ12_0263
crossref_primary_10_1111_j_1600_079X_2011_00888_x
crossref_primary_10_30802_AALAS_JAALAS_21_000123
crossref_primary_10_3892_etm_2022_11197
crossref_primary_10_1152_ajpgi_00288_2014
crossref_primary_10_1038_nrc3507
Cites_doi 10.1016/S0006-2952(01)00634-7
10.1093/jnci/95.11.825
10.1158/0008-5472.CAN-05-1945
10.1023/A:1011237000609
10.1093/jnci/dji190
10.1093/jnci/93.20.1557
10.1158/0008-5472.CAN-07-2485
10.1007/s10549-004-6603-z
10.1093/oxfordjournals.aje.a114569
10.1016/j.canlet.2005.04.025
10.1097/00001648-200101000-00013
10.1097/01.ede.0000190539.03500.c1
10.1093/aje/kwj232
10.1093/jjco/hyd134
10.1093/jnci/djn171
10.1385/ENDO:27:2:179
10.1289/ehp.10200
10.1093/jnci/93.20.1563
10.2174/1568026023394407
ContentType Journal Article
Copyright The Author(s) 2009
Copyright_xml – notice: The Author(s) 2009
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1177/1534735409352320
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
CrossRef
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1552-695X
EndPage 353
ExternalDocumentID 20042410
10_1177_1534735409352320
10.1177_1534735409352320
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: R01CA85408
– fundername: NIEHS NIH HHS
  grantid: 1R21ES11659
GroupedDBID ---
-TM
01A
0R~
29J
4.4
53G
54M
5GY
5VS
7RV
8FI
8FJ
AABMB
AABOD
AADUE
AAJPV
AAJQC
AAQDB
AARDL
AARIX
AASGM
AAWTL
ABAFQ
ABAWP
ABEIX
ABFWQ
ABKRH
ABQXT
ABRHV
ABUWG
ABVFX
ACARO
ACDSZ
ACDXX
ACGFS
ACOFE
ACROE
ACRPL
ADBBV
ADEBD
ADNMO
ADOGD
ADYCS
ADZZY
AENEX
AEQLS
AERKM
AEUHG
AEWDL
AEXNY
AFCOW
AFEET
AFKRA
AFKRG
AFRWT
AFUIA
AFWMB
AGNHF
AGQPQ
AHHFK
AJUZI
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
ARTOV
ASPBG
AUTPY
AVWKF
AYAKG
AZFZN
B8M
BCNDV
BDDNI
BENPR
BKEYQ
BKSCU
BPHCQ
BSEHC
BVXVI
BYIEH
CAG
CCPQU
CDWPY
CFDXU
COF
CS3
DC-
DC.
DOPDO
DU5
EBS
EJD
EMOBN
F5P
FEDTE
FYUFA
GROUPED_DOAJ
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
H13
HF~
HVGLF
HYE
HZ~
IAO
IEA
IHR
INH
INR
J8X
K.F
KQ8
N9A
NAPCQ
O9-
OK1
P.B
P2P
PHGZM
PHGZT
PIMPY
PQQKQ
RIG
ROL
RPM
S01
SAUOL
SCDPB
SCNPE
SFC
UDS
UKHRP
ZGI
ZONMY
ZPPRI
ZRKOI
ZSSAH
AAYXX
ACHEB
CITATION
PPXIY
PUEGO
CGR
CUY
CVF
ECM
EIF
M4V
NPM
7X8
ID FETCH-LOGICAL-c444t-1ae086d41c6aad07e91684f6c30109e715613b259e1d881c367f20784af7440b3
IEDL.DBID AFRWT
ISSN 1534-7354
1552-695X
IngestDate Fri Sep 05 14:20:17 EDT 2025
Thu Apr 03 06:56:17 EDT 2025
Thu Apr 24 22:58:14 EDT 2025
Wed Sep 10 04:31:18 EDT 2025
Tue Jun 17 22:31:26 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords light at night
breast cancer
melatonin
circadian disruption
tumor metabolism
Language English
License https://journals.sagepub.com/page/policies/text-and-data-mining-license
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c444t-1ae086d41c6aad07e91684f6c30109e715613b259e1d881c367f20784af7440b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://journals.sagepub.com/doi/pdf/10.1177/1534735409352320
PMID 20042410
PQID 733789264
PQPubID 23479
PageCount 7
ParticipantIDs proquest_miscellaneous_733789264
pubmed_primary_20042410
crossref_primary_10_1177_1534735409352320
crossref_citationtrail_10_1177_1534735409352320
sage_journals_10_1177_1534735409352320
PublicationCentury 2000
PublicationDate 2009-12-01
PublicationDateYYYYMMDD 2009-12-01
PublicationDate_xml – month: 12
  year: 2009
  text: 2009-12-01
  day: 01
PublicationDecade 2000
PublicationPlace Los Angeles, CA
PublicationPlace_xml – name: Los Angeles, CA
– name: United States
PublicationTitle Integrative cancer therapies
PublicationTitleAlternate Integr Cancer Ther
PublicationYear 2009
Publisher SAGE Publications
Publisher_xml – name: SAGE Publications
References Stevens RG, Rea MS 2001; 12
Hansen J. 2002; 12
Viswanathan AN, Hankinson SE, Schernhammer ES 2007; 67
Sauer LA, Dauchy RT, Blask DE 2001; 61
Kubo T., Ozasa K., Mikami K. 2006; 164
Blask DE, Sauer LA, Dauchy RT 2002; 2
Stevens RG 1987; 125
Hrushesky WJM. 2000; 30
Cos S., Mediavilla D., Martinez-Campa C. 2006; 235
Blask DE, Dauchy RT, Sauer LA 2005; 46
Stevens RG, Blask DE, Brainard GC 2007; 115
Davis S., Mirick DK, Stevens RG 2001; 93
Schernhammer ES, Hankinson SE 2005; 97
Canaple L., Kakizawa T., Laudet V. 2003; 63
Blask DE, Brainard GC, Dauchy RT 2005; 65
Schernhammer ES, Laden F., Speizer FE 2001; 93
Schernhammer ES, Kroenke CH, Laden F. 2006; 17
Schernhammer ES, Laden F., Speizer FE 2003; 95
Blask DE, Dauchy RT, Sauer LA 2005; 27
You S., Wood PA, Xiong Y. 2005; 91
Schernhammer ES, Berrino F., Krogh V. 2008; 100
atypb9
atypb8
Blask DE (atypb7) 2005; 46
atypb19
Sauer LA (atypb5) 2001; 61
atypb15
atypb16
atypb17
Canaple L. (atypb2) 2003; 63
atypb18
atypb11
atypb22
atypb12
atypb13
atypb14
atypb1
atypb3
atypb20
atypb10
atypb21
atypb4
atypb6
References_xml – volume: 93
  start-page: 1563
  year: 2001
  end-page: 1568
  article-title: Rotating night shifts and risk of breast cancer in women participating in the nurses’ health study
  publication-title: J Natl Cancer Inst
– volume: 67
  start-page: 10618
  year: 2007
  end-page: 10622
  article-title: Night shift work and the risk of endometrial cancer
  publication-title: Cancer Res
– volume: 30
  start-page: 529
  year: 2000
  end-page: 533
  article-title: The temporal organization of life: the impact of multifrequency non-linear biological time structure upon the host-cancer balance
  publication-title: Jpn J Clin Oncol
– volume: 27
  start-page: 179
  year: 2005
  end-page: 188
  article-title: Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal
  publication-title: Endocrine
– volume: 12
  start-page: 74
  year: 2002
  end-page: 77
  article-title: Increased breast cancer among women who work predominantly at night
  publication-title: Epidemiology
– volume: 100
  start-page: 898
  year: 2008
  end-page: 905
  article-title: Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women
  publication-title: J Natl Cancer Inst
– volume: 95
  start-page: 825
  year: 2003
  end-page: 828
  article-title: Night-shift work and risk of colorectal cancer in the nurses’ health study
  publication-title: J Natl Cancer Inst
– volume: 93
  start-page: 1557
  year: 2001
  end-page: 1562
  article-title: Night shift work, light at night, and risk of breast cancer
  publication-title: J Natl Cancer Inst
– volume: 61
  start-page: 1455
  year: 2001
  end-page: 1462
  article-title: Polyunsaturated fatty acids, melatonin, and cancer prevention
  publication-title: Biochem Pharmacol
– volume: 2
  start-page: 113
  year: 2002
  end-page: 132
  article-title: Melatonin as a chronobiotic/ anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy
  publication-title: Curr Top Med Chem
– volume: 46
  start-page: 1358
  year: 2005
  article-title: Oral melatonin supplementation in rats and a human subject suppresses the growth activity of steroid receptor negative human breast cancer xenografts in female nude rats via an MT1 receptor-mediated suppression of signal transduction and linoleic acid uptake and metabolism [abstract 5776]
  publication-title: Am Assoc Cancer Res
– volume: 125
  start-page: 556
  year: 1987
  end-page: 561
  article-title: Electric power use and breast cancer: a hypothesis
  publication-title: Am J Epidemiol
– volume: 164
  start-page: 549
  year: 2006
  end-page: 555
  article-title: Prospective cohort study of the risk of prostate cancer among rotating-shift workers: findings from the Japan collaborative cohort study
  publication-title: Am J Epidemiol
– volume: 97
  start-page: 1084
  year: 2005
  end-page: 1087
  article-title: Urinary melatonin levels and breast cancer risk
  publication-title: J Natl Cancer Inst
– volume: 115
  start-page: 1357
  year: 2007
  end-page: 1362
  article-title: Meeting report: the role of environmental lighting and circadian disruption in cancer and other diseases
  publication-title: Environ Health Perspect
– volume: 235
  start-page: 266
  year: 2006
  end-page: 271
  article-title: Exposure to light-at-night increases the growth of DMBA-induced mammary adenocarcinoma in rats
  publication-title: Cancer Lett
– volume: 17
  start-page: 108
  year: 2006
  end-page: 111
  article-title: Night work and risk of breast cancer
  publication-title: Epidemiology
– volume: 65
  start-page: 11174
  year: 2005
  end-page: 11184
  article-title: Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats
  publication-title: Cancer Res
– volume: 63
  start-page: 7545
  year: 2003
  end-page: 7552
  article-title: The days and nights of cancer cells
  publication-title: Cancer Res
– volume: 12
  start-page: 279
  year: 2001
  end-page: 287
  article-title: Light in the built-in environment: potential role of circadian disruption in endocrine disruption and breast cancer
  publication-title: Cancer Causes Control
– volume: 91
  start-page: 47
  year: 2005
  end-page: 60
  article-title: Daily coordination of cancer growth and circadian clock gene expression
  publication-title: Breast Cancer Res Treat
– volume: 46
  start-page: 1358
  year: 2005
  ident: atypb7
  publication-title: Am Assoc Cancer Res
– volume: 61
  start-page: 1455
  year: 2001
  ident: atypb5
  publication-title: Biochem Pharmacol
  doi: 10.1016/S0006-2952(01)00634-7
– ident: atypb18
  doi: 10.1093/jnci/95.11.825
– ident: atypb6
  doi: 10.1158/0008-5472.CAN-05-1945
– ident: atypb11
  doi: 10.1023/A:1011237000609
– ident: atypb20
  doi: 10.1093/jnci/dji190
– ident: atypb14
  doi: 10.1093/jnci/93.20.1557
– ident: atypb17
  doi: 10.1158/0008-5472.CAN-07-2485
– ident: atypb22
  doi: 10.1007/s10549-004-6603-z
– ident: atypb10
  doi: 10.1093/oxfordjournals.aje.a114569
– ident: atypb8
  doi: 10.1016/j.canlet.2005.04.025
– volume: 63
  start-page: 7545
  year: 2003
  ident: atypb2
  publication-title: Cancer Res
– ident: atypb9
– ident: atypb13
  doi: 10.1097/00001648-200101000-00013
– ident: atypb16
  doi: 10.1097/01.ede.0000190539.03500.c1
– ident: atypb19
  doi: 10.1093/aje/kwj232
– ident: atypb1
  doi: 10.1093/jjco/hyd134
– ident: atypb21
  doi: 10.1093/jnci/djn171
– ident: atypb3
  doi: 10.1385/ENDO:27:2:179
– ident: atypb12
  doi: 10.1289/ehp.10200
– ident: atypb15
  doi: 10.1093/jnci/93.20.1563
– ident: atypb4
  doi: 10.2174/1568026023394407
SSID ssj0021065
Score 2.1050022
SecondaryResourceType review_article
Snippet The circadian production of melatonin by the pineal gland during the night provides an inhibitory signal to tissue-isolated steroid receptor SR+ and — MCF-7...
The circadian production of melatonin by the pineal gland during the night provides an inhibitory signal to tissue-isolated steroid receptor SR+ and - MCF-7...
SourceID proquest
pubmed
crossref
sage
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 347
SubjectTerms Animals
Anticarcinogenic Agents - pharmacology
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Cell Growth Processes - drug effects
Cell Growth Processes - physiology
Cell Proliferation - drug effects
Circadian Rhythm - physiology
Female
Humans
Light
Linoleic Acid - metabolism
Linoleic Acids - metabolism
Melatonin - blood
Melatonin - pharmacology
Melatonin - physiology
Neoplasm Transplantation
Photoperiod
Rats
Rats, Nude
Receptors, Melatonin - physiology
Signal Transduction - drug effects
Transplantation, Heterologous
Title Circadian Stage-Dependent Inhibition of Human Breast Cancer Metabolism and Growth by the Nocturnal Melatonin Signal: Consequences of Its Disruption by Light at Night in Rats and Women
URI https://journals.sagepub.com/doi/full/10.1177/1534735409352320
https://www.ncbi.nlm.nih.gov/pubmed/20042410
https://www.proquest.com/docview/733789264
Volume 8
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LT-MwELZ4SIjLCthXeWkOCGkP2Sax27RcVlC2PLTtgYeWW-Q4DkSiKWqcA7-Mv7czjtNdFoG4VZHtqeJx8s18X2YY29OJL32lSKnGhSeUVF6fC9K68jTxM9FPJCX0R-Pu6bU4v-ncLLCi-RbG3cHyO8mq8B_ZhzWdbspGtx3J2MZjSi1zBbF4CAn8H5WZxHW2u2mqQVeInq4mxGwr0kM-es3XbYtsmSqX44lYPhxe_L6ah2gYIHXqCqvCIwN_ic0XNp-_yF6g02fKMPuyGq6xDw5lwmHtFutsQRcbbGXkePSP7GmQz5StSgCINm-1d-x64Ro4K-7yxOq4YJqBzfHDESnXDQzIQ2Yw0gY95z4vJyCLFE4wkDd3kDwCYkkYT4mTIOMjktlRshcu81u8cACDf5TbtPiZKeE4L2eVfWzRCr8oVQDSwNj-wLkXEgeRGdtq8xO7Hv68Gpx6roWDp4QQxgukxpgpFYHqSpn6kUY02hNZV3Gi5HQUUPySYAimg7TXCxTvRlmIqEXIjCoXJvwzWyqmhf7KIOyEkfY1Ol0HYybBpYq4ykSaSh6mmQ5brN3sR6xcfXNqs3EfB66k-f872GLf5jMe6toeb4yFZotjPIDEqshCT6syjjiPen3ElS32pd76-WKhJZYDnLxPvhA3zv2qlc33Dtxiq6FrZOEH22zJzCq9g-jIJLvOpXdtduEPXI8IRA
linkProvider SAGE Publications
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9swDBaGFOh2GbrulT42HoYBO3izLfmR3tp0WbLFOXQp1pshy3JroHWKWDn0l_XvlVSUrF2xYTfDECnDpOTvE2mSsQ-68KWvFGWqceEJJZXX44JyXXlZ-JXoFZIO9LNJPDwV38-is3utvtwbbD9TWhU-kd2s16ub_hOPOHXLFRTAQzSAbH1DRH6cdtjG4eDk13TNtpDrRMtiqcIjgd8xykc6Hn6THgHNB0le9rsz2GLPHWCEw6WFX7Anutlmm5kLib9kt_16rmyBAUDgeK69Y9fW1sCouagLm5IFswrscT0cURK6gT4Zew6ZNugEl3V7BbIp4RtycnMBxQ0gLITJjMILNHlGGXN0bgs_63O8cQD9e0nYpHxkWjiu2_nC7kCkYUysH6SBib1A2ROJg2ga2zXzFTsdfJ32h57rxuApIYTxAqmR_pQiULGUpZ9oBJapqGLFKbqmk4CoSIFsSgdlmgaKx0kVIgARsqIihAV_zTrNrNFvGYRRmGhfo_9ESH8ElyrhqhJlKXlYVjrssi8re-TKlSqnjhmXeeCqk_9pwS77tJa4Xpbp-MdYWJk4x7VEARLZ6NmizRPOk7SHELHL3ixNv1YW2hhxgMIfyRfylZ_-dZad_x34nj0dTrNxPh5NfuyyZ6HrT-EHe6xj5gu9j6DHFO-ce98BAKX0rQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1NT9tAEF2hIKFeqlIKTQvtHCqkHtzY3k3s9AZJAykkQhQEN2u9uw6WqIPizaG_rH-vM5tNyoeKerOs_bA8s-v3dp5nGPtk8lCGSpFSjYtAKKmCLhekdeU6DwvRzSUd6I_GneNL8f26fe21OfQvjH-D9ReSVeETuc2aVvedLlo-xtjCVUoVcwUF8RARIGNfR1aThg22fjA4v7pYMS7kO-1FwlQRUIe_cconYzz8Lj0Bmw-EXu7bM3jFXnrQCAcLK2-yNVO9ZhsjHxbfYr975Uy5JAOA4HFigr4vbWthWN2UuZNlwbQAd2QPhyREt9Ajg89gZCw6wm1Z_wRZaThCXm5vIP8FCA1hPKUQA00-ItUcnd3Cj3KCN75C754QmwYf2hr6ZT2bu12IRjgl5g_SwthdYN9ziY1oGlc58w27HHy76B0HviJDoIQQNoikQQqkRaQ6UuowMQguU1F0FKcIm0kioiM5MioT6TSNFO8kRYwgRMiCEhHmfJs1qmll3jKI23FiQoM-1EYKJLhUCVeF0FryWBcmbrLW0h6Z8unKqWrGbRb5DOWPLdhkn1c97hapOp5pC0sTZ7ieKEgiKzOd11nCeZJ2ESY22c7C9KvBYhcnjrDzPvlCtvTVf87y7n8bfmQbZ_1Bdjocn7xnL2JfoiKMdlnDzuZmD3GPzT947_4DvED1vQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Circadian+Stage-Dependent+Inhibition+of+Human+Breast+Cancer+Metabolism+and+Growth+by+the+Nocturnal+Melatonin+Signal%3A+Consequences+of+Its+Disruption+by+Light+at+Night+in+Rats+and+Women&rft.jtitle=Integrative+cancer+therapies&rft.au=Blask%2C+David+E.&rft.au=Dauchy%2C+Robert+T.&rft.au=Brainard%2C+George+C.&rft.au=Hanifin%2C+John+P.&rft.date=2009-12-01&rft.pub=SAGE+Publications&rft.issn=1534-7354&rft.eissn=1552-695X&rft.volume=8&rft.issue=4&rft.spage=347&rft.epage=353&rft_id=info:doi/10.1177%2F1534735409352320&rft.externalDocID=10.1177_1534735409352320
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1534-7354&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1534-7354&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1534-7354&client=summon